A 62-year-old woman confronts stage 4 kidney disease after a diagnosis of focal segmental glomerulosclerosis (FSGS) in 2001. Following several years of treatment and a brief remission, she now highlights the importance of preparing for what lies ahead.

A new generation of medications first developed for diabetes is now offering hope for chronic kidney disease patients. Three types of these drugs, including one famously known as Ozempic, are transforming the outlook for individuals who have long waited for more effective treatment options.